Akebia Therapeutics (AKBA) Current Leases (2013 - 2020)
Akebia Therapeutics (AKBA) posted quarterly Current Leases of $5.1 million for Q1 2020, down 83.72% year-over-year from $31.3 million in Q2 2019, and up 2.14% quarter-over-quarter from $5.0 million in Q4 2019.
Akebia Therapeutics (AKBA) Current Leases (2013 - 2020) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Current Leases for 4 consecutive years, with $5.1 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Current Leases fell 83.72% year-over-year to $5.1 million; the TTM figure through Mar 2020 stood at $5.1 million (down 83.72% YoY), while the FY2019 annual figure was $5.0 million, changed N/A from the prior year.
- Current Leases climbed to $5.1 million in Q1 2020 per AKBA's latest filing, from $5.0 million in the prior quarter.
- Across five years, Current Leases topped out at $31.3 million in Q1 2019 and bottomed at $4.8 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 5.10 Mn |
| Dec 31, 2019 | 4.99 Mn |
| Sep 30, 2019 | 4.88 Mn |
| Jun 30, 2019 | 4.78 Mn |
| Mar 31, 2019 | 31.30 Mn |
| Jun 30, 2014 | 3,939.00 |
| Mar 31, 2014 | 3,911.00 |
| Dec 31, 2013 | 3,912.00 |